U.S. MarketsAugust 4 at 04:00 PM

Gilead Sciences Inc. (GILD) Q2 2026 (USD) Adj. EPS -8.45 (exp. -7.26), Revenue 7.80bln (exp. 7.40bln)

StockNow breaking-news AI analysis

Gilead reported a larger-than-expected adjusted EPS loss in Q2 2026 despite beating revenue estimates. Investor focus remains on the conservative outlook for the HIV prevention drug Yeztugo.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLY Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy